BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo

Core Insights - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as one of the 20 Best Investments for 2026, indicating strong future potential in the market [1]. Financial Analysis - Wells Fargo & Company has raised its price target for BMRN from $70 to $75 while maintaining an Overweight rating, suggesting that the stock is currently undervalued, particularly when excluding Voxzogo from the analysis [2]. - BioMarin completed an $850 million offering of 5.500% senior unsecured notes maturing in 2034, with proceeds primarily aimed at supporting the acquisition of Amicus Therapeutics and related expenses [3]. - The proceeds from the notes are held in escrow until the acquisition is finalized, with a provision for redemption if the deal does not close by the deadline [4]. Company Overview - BioMarin is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases, particularly through enzyme replacement and gene-targeted treatments [5].